학술논문
Antithrombotic Treatment of Embolic Stroke of Undetermined Source
Document Type
article
Author
Diener, Hans-Christoph; Sacco, Ralph L; Easton, J Donald; Granger, Christopher B; Bar, Michal; Bernstein, Richard A; Brainin, Michael; Brueckmann, Martina; Cronin, Lisa; Donnan, Geoffrey; Gdovinová, Zuzana; Grauer, Claudia; Kleine, Eva; Kleinig, Timothy J; Lyrer, Philippe; Martins, Sheila; Meyerhoff, Juliane; Milling, Truman; Pfeilschifter, Waltraud; Poli, Sven; Reif, Michal; Rose, David Z; Šaňák, Daniel; Schäbitz, Wolf-Rüdiger
Source
Stroke. 51(6)
Subject
Language
Abstract
Background and Purpose- The RE-SPECT ESUS trial (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) tested the hypothesis that dabigatran would be superior to aspirin for the prevention of recurrent stroke in patients with embolic stroke of undetermined source. This exploratory subgroup analysis investigates the impact of age, renal function (both predefined), and dabigatran dose (post hoc) on the rates of recurrent stroke and major bleeding. Methods- RE-SPECT ESUS was a multicenter, randomized, double-blind trial of dabigatran 150 or 110 mg (for patients aged ≥75 years and/or with creatinine clearance 30 to